Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France
OBJECTIVES: To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and INI-naïve HIV-infected adults with at least two classes resistance compared to raltegravir (RAL), by adapting previously published Anti-Retro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699888/ https://www.ncbi.nlm.nih.gov/pubmed/26714188 http://dx.doi.org/10.1371/journal.pone.0145885 |
_version_ | 1782408244958855168 |
---|---|
author | Pialoux, Gilles Marcelin, Anne-Geneviève Despiégel, Nicolas Espinas, Caroline Cawston, Hélène Finkielsztejn, Laurent Laurisse, Audrey Aubin, Céline |
author_facet | Pialoux, Gilles Marcelin, Anne-Geneviève Despiégel, Nicolas Espinas, Caroline Cawston, Hélène Finkielsztejn, Laurent Laurisse, Audrey Aubin, Céline |
author_sort | Pialoux, Gilles |
collection | PubMed |
description | OBJECTIVES: To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and INI-naïve HIV-infected adults with at least two classes resistance compared to raltegravir (RAL), by adapting previously published Anti-Retroviral Analysis by Monte Carlo Individual Simulation (ARAMIS) model. METHODS: ARAMIS is a microsimulation Markov model with a lifetime time horizon and a monthly cycle length. Health states are defined as with or without opportunistic infection and death. In the initial cohort, efficacy and safety data were derived from a phase III study comparing DTG to RAL. Antiretroviral treatment algorithms, accounting for patient history, were based on French guidelines and experts opinion. Costs are mainly including treatment costs, routine HIV and opportunistic infection care, and death. Utilities depend on CD4+ cell count and the occurrence of opportunistic infections. RESULTS: The ARAMIS model indicates in the TE population that DTG compared to RAL over a life time is associated with 0.35 additional quality-adjusted life years (QALY; 10.75 versus 10.41) and additional costs of €7,266 (€390,001 versus €382,735). DTG increased costs are mainly related to a 9.1-month increase in life expectancy for DTG compared with RAL, and consequently a longer time spent on ART. The incremental cost-effectiveness ratio (ICER) for DTG compared with RAL is €21,048 per QALY gained. About 83% and 14% of total lifetime costs are associated with antiretroviral therapy and routine HIV care respectively. Univariate deterministic sensitivity analyses demonstrate the robustness of the model. CONCLUSION: DTG is cost-effective in the management of TE INI naive patients in France, from a collective perspective. These results could be explained by the superior efficacy of DTG in this population and its higher genetic barrier to resistance compared to RAL. These data need to be confirmed with longer-term real life data. |
format | Online Article Text |
id | pubmed-4699888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-46998882016-01-14 Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France Pialoux, Gilles Marcelin, Anne-Geneviève Despiégel, Nicolas Espinas, Caroline Cawston, Hélène Finkielsztejn, Laurent Laurisse, Audrey Aubin, Céline PLoS One Research Article OBJECTIVES: To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and INI-naïve HIV-infected adults with at least two classes resistance compared to raltegravir (RAL), by adapting previously published Anti-Retroviral Analysis by Monte Carlo Individual Simulation (ARAMIS) model. METHODS: ARAMIS is a microsimulation Markov model with a lifetime time horizon and a monthly cycle length. Health states are defined as with or without opportunistic infection and death. In the initial cohort, efficacy and safety data were derived from a phase III study comparing DTG to RAL. Antiretroviral treatment algorithms, accounting for patient history, were based on French guidelines and experts opinion. Costs are mainly including treatment costs, routine HIV and opportunistic infection care, and death. Utilities depend on CD4+ cell count and the occurrence of opportunistic infections. RESULTS: The ARAMIS model indicates in the TE population that DTG compared to RAL over a life time is associated with 0.35 additional quality-adjusted life years (QALY; 10.75 versus 10.41) and additional costs of €7,266 (€390,001 versus €382,735). DTG increased costs are mainly related to a 9.1-month increase in life expectancy for DTG compared with RAL, and consequently a longer time spent on ART. The incremental cost-effectiveness ratio (ICER) for DTG compared with RAL is €21,048 per QALY gained. About 83% and 14% of total lifetime costs are associated with antiretroviral therapy and routine HIV care respectively. Univariate deterministic sensitivity analyses demonstrate the robustness of the model. CONCLUSION: DTG is cost-effective in the management of TE INI naive patients in France, from a collective perspective. These results could be explained by the superior efficacy of DTG in this population and its higher genetic barrier to resistance compared to RAL. These data need to be confirmed with longer-term real life data. Public Library of Science 2015-12-29 /pmc/articles/PMC4699888/ /pubmed/26714188 http://dx.doi.org/10.1371/journal.pone.0145885 Text en © 2015 Pialoux et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Pialoux, Gilles Marcelin, Anne-Geneviève Despiégel, Nicolas Espinas, Caroline Cawston, Hélène Finkielsztejn, Laurent Laurisse, Audrey Aubin, Céline Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France |
title | Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France |
title_full | Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France |
title_fullStr | Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France |
title_full_unstemmed | Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France |
title_short | Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France |
title_sort | cost-effectiveness of dolutegravir in hiv-1 treatment-experienced (te) patients in france |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699888/ https://www.ncbi.nlm.nih.gov/pubmed/26714188 http://dx.doi.org/10.1371/journal.pone.0145885 |
work_keys_str_mv | AT pialouxgilles costeffectivenessofdolutegravirinhiv1treatmentexperiencedtepatientsinfrance AT marcelinannegenevieve costeffectivenessofdolutegravirinhiv1treatmentexperiencedtepatientsinfrance AT despiegelnicolas costeffectivenessofdolutegravirinhiv1treatmentexperiencedtepatientsinfrance AT espinascaroline costeffectivenessofdolutegravirinhiv1treatmentexperiencedtepatientsinfrance AT cawstonhelene costeffectivenessofdolutegravirinhiv1treatmentexperiencedtepatientsinfrance AT finkielsztejnlaurent costeffectivenessofdolutegravirinhiv1treatmentexperiencedtepatientsinfrance AT laurisseaudrey costeffectivenessofdolutegravirinhiv1treatmentexperiencedtepatientsinfrance AT aubinceline costeffectivenessofdolutegravirinhiv1treatmentexperiencedtepatientsinfrance |